20249-16-5

Usage

Uses

Used in Pharmaceutical Industry:
3-OXO-CYCLOBUTANECARBONITRILE is used as an intermediate in the synthesis of various pharmaceuticals for its ability to facilitate the creation of complex organic molecules, contributing to the development of new drugs and medicines.
Used in Agrochemical Production:
In the agrochemical industry, 3-OXO-CYCLOBUTANECARBONITRILE is utilized as a key intermediate in the production of various agrochemicals, playing a crucial role in the development of pesticides and other agricultural chemicals to enhance crop protection and yield.
Used in Dye Manufacturing:
3-OXO-CYCLOBUTANECARBONITRILE is employed as an intermediate in the manufacturing of dyes, where its reactivity and versatility contribute to the synthesis of a wide range of colorants used in various industries, including textiles, plastics, and printing.
Used as a Solvent and Reagent:
3-OXO-CYCLOBUTANECARBONITRILE is used as a solvent and reagent in various chemical processes due to its ability to dissolve a wide range of substances and participate in numerous chemical reactions, aiding in the advancement of chemical research and industrial applications.

InChI:InChI=1/C5H5NO/c6-3-4-1-5(7)2-4/h4H,1-2H2

Upstream product

• 15760-35-7 3-methylenecyclobutanecarbonitrile 
• 22020-87-7 5-nitro-2-pentanone 
• 27607-77-8 trimethylsilyl trifluoromethanesulfonate 
• 339529-30-5 3-oxo-2-trimethylsilyl-cyclobutane-carbonitrile 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 

Downstream Products

• 29545-82-2 cis-oder trans-1-Chloro-1,3-cyclobutan-dinitril 
• 29545-81-1 1,3-Bicyclobutan-dinitril 
• 51934-03-3 3-hydroxy-3-vinylcyclobutane-1-carbonitrile 
• 30494-25-8 3-hydroxy-3-phenylcyclobutane-1-carbonitrile 
• 27744-70-3 3,3-dichlorocyclobutanecarbonitrile 
• 86770-80-1 3,3-difluorocyclobutane-1-carbonitrile 
• 1153949-98-4 3-(cyanomethylene)cyclobutane-1-carbonitrile 
• 20249-17-6 3-hydroxycyclobutane-1-carbonitrile 
• 938064-64-3 3-(4-methoxy-benzyloxy)-cyclobutanecarbonitrile 

Relevant academic research and scientific papers

The exhaustive silylation of 5-nitro-pentan-2-one: Novel processes and opportunities

Treatment of 5-nitro-pentan-2-one (1) with Me3SiOTf/Et3N leads to initial silylation of the C(O)Me-group to give regioisomeric silyl enol ethers 2a and 2b followed by double silylation of the NO2-group furnishing a mixture of N,N-bis(silyloxy)enamine 4a and enoxime TMS ether 6. Employment of a large excess of Me3SiOTf/Et3N triggers a cascade of eliminations and silylations to give a mixture of (E)-4-trimethylsilyloxy-2-trimethylsilyl-pent-2,4-dienenitrile (8) and 3-oxo-1-(1,1,1-trimethylsilyl)-1-cyclobutanecarbonitrile (9). The use of Me3SiCl/DBU changes the selectivity of silylation of 1 to give silyl nitronate 2c.

2 Tyrosine kinase mediated signal transduction inhibitors

Disclosed herein are compounds of Formula (), and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, X, X, X, X, X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.

ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS

The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.

IMIDAZO[1,2-A]PYRIDINES AS SOLUBLE GUANYLATE CYCLASE STIMULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists

Transient receptor potential vanilloid 3 (TRPV3) is a Ca2+- and Na+-permeable channel with a unique expression pattern. TRPV3 is found in both neuronal and non-neuronal tissues, including dorsal root ganglia, spinal cord, and keratinocytes. Recent studies suggest that TRPV3 may play a role in inflammation, pain sensation, and skin disorders. TRPV3 studies have been challenging, in part due to a lack of research tools such as selective antagonists. Herein, we provide the first detailed report on the development of potent and selective TRPV3 antagonists featuring a pyridinyl methanol moiety. Systematic optimization of pharmacological, physicochemical, and ADME properties of original lead 5a resulted in identification of a novel and selective TRPV3 antagonist 74a, which demonstrated a favorable preclinical profile in two different models of neuropathic pain as well as in a reserpine model of central pain.

DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS

The present disclosure is based, in part, on the discovery that disclosed compounds can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.

COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY

The present disclosure features compounds such as those having the Formulae (Ila), (lIb), (lIc), (Ild), (IlIa), and (Illb), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (Ila), (lIb), (lIc), (lId), (IlIa), or (Illb).

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.

N-ACYLETHANOLAMINE HYDROLYZING ACID AMIDASE (NAAA) INHIBITORS AND THEIR USE THEREOF

A compound is represented as Formula I, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Compounds of Formula I are inhibitors of N-acylethanolamine hydrolyzing acid amidase (NAAA). The present technology is directed to compounds, compositions, and methods to inhibit N-acylethanolamine hydrolyzing acid amidase and to treat N-acylethanolamine hydrolyzing acid amidase mediated conditions in a subject.

FUSED IMIDAZOLE COMPOUNDS

The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA α5) and act as GABAA α5 negative allosteric modulators (GABAA α5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA α5 such as Alzheimer's disease.